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INTRODUCTION
In recent decades the application of the multimo-
dal enhanced recovery strategy for surgical treatment 
of patients with colorectal cancer has convincingly prov-
en its efficiency. According to the results of the survey 
of 123 major centers of colorectal surgery worldwide in 
2012, the enhanced recovery program (ERP) was ad-
justed as a standard option in 63% of these centers [1]. 
Results of the meta-analysis of 1353 trials over the past 
20 years, provided by J. Zhao et al., suggest undoubt-
able advantages of the ERP application not only because 
of the signi ficant reduction of the postoperative morbi-
dity and mortality, but also because of the patient’s life 
quality improvement and treatment costs reduction [2].
Multiple clinical and experimental studies have pro ven 
that the main effective component of the ERP is the de-
crease of the host’s stress response to the surgical injury, 
which is demonstrated by the reduction of the proinflam-
matory cytokines expression, leading to the minimization 
of the consequences of the systemic inflammatory re-
sponse syndrome [3–6]. Prevention of such critical me-
tabolic issues as protein-energy insufficiency syndrome, 
postoperative insulin resistance and hypermetabolism-
hypercatabolism syndrome, together with malignant 
cell’s biochemical atypism, significantly deplete organ-
ism’s energy resources, causing a negative impact on cel-
lular and humoral immunity, leading to the deve lopment 
of immunosuppression [7]. These factors create a patholo-
gical foundation for the development of the main type of 
postoperative complications, which accompany colorec-
tal surgery in all its way of development [6].
Despite the reduction of the postoperative reco very 
period, morbidity and mortality, patient’s life quali-
ty improvement, the impact of the ERP on long-term 
outcomes of colon cancer patients surgical treatment 
remains unclear. In theory such impact seems possible 
due to the reduction of postoperative complications, re-
covery, maintenance of normal immune system func-
tioning and also due to the reduction of contra-indica-
tions to the adjuvant treatment and the term reduction 
before its beginning. Nowadays, more and more stu dies 
deal with the influence of postoperative complications 
on the long-term outcomes of surgical treatment of co-
lon cancer patients. The results of such studies prove 
the existence of such consistent pattern, underlining that 
the ways to prevent the development of such complica-
tions can also become an instrument for the long-term 
outcome improvement [6, 8, 9].
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Application of the multimodal enhanced recovery program (ERP) proved its effec-
tiveness in surgical treatment of patients with colon cancer. The impact of an ERP 
on the long-term outcomes remains a challenge. Aim of the study: to assess the im-
pact of an ERP on the long-term outcomes of the surgical treatment of colon can-
cer patients. Object and methods: a total of 230 patients, who underwent curative 
surgery for colon cancer from 2008 to 2013, were enrolled and divided into main 
(130 patients) and control group (100 patients). Results: no significant difference 
in antropometric data, tumor site, disease stage and surgery type was observed. 
Grade II–IV according to the Clavien — Dindo classification of surgical compli-
cations was determined in 11 (8.5%) patients of main group and in 20 (20.0%) 
patients of control group (р < 0.05) with postoperative mortality 0.8 and 2.0%, re-
spectively (р < 0.05). Overall 3-year survival differed significantly: 88.4 ± 9.6% — 
in main and 72.2 ± 7.6% — in control group (р < 0.05) with insigni ficant shift in 
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Aim of the study: to evaluate the impact of 
the multimo dal ERP on the long-term outcomes (over-
all and recurrence-free 3-year survival) of the surgical 
treatment of colon cancer patients.
MATERIALS AND METHODS
Over the 2008 to 2013 period a randomized trial, 
aimed to evaluate the impact of the developed ERP 
on short- and long-term outcomes of surgical treat-
ment of colon cancer patients was held. Inclusion cri-
teria were: presence of histologically verified colon 
ade nocarcinoma stage I–IV (T1–4N0–2M0–1); age 
above 18 years, intent of rather curative or palliative 
surgery for resectable disease, patient’s common status 
≤ 2 by ECOG (Eastern Cooperative Oncology Group) 
or ≥ 50 by Karnovsky scale; a signed informed con-
cern for treatment. Patients with the complicated di-
sease (ile us, peritonitis, acute bleeding), with previous 
explorative laparotomies, symptomatic procedures; pa-
tients with synchronous and/or metachronous malig-
nancies and with tumors of non-epithelial origin were 
excluded from the trial.
After the randomization the patients were distributed 
into the main (enhanced recovery pathway) and control 
group (standard care). Adaptative design of randomiza-
tion was used — enrollment started in 1 : 1 proportion, 
however according to the trial conditions, if a certain 
group appeared to be non-representative, additional en-
rollment was declared until both groups reached repre-
sentative values.
The main statements of the ERP were as follows:
1. Preoperative period: no mechanical bowel prepa-
ration; no preoperative starvation — last uptake of car-
bohydrate enriched solutions 6–8 hours prior to surgery.
2. Intraoperative period: epidural analgesia with 
0.125% bupivacaine + phentanyle solution on the le-
vel of ThVIII–X 8–9 ml per hour, using of nonsteroid anti- 
inflammatory drugs (NSAIDs); laparoscopic or laparo-
scopy-assisted procedures. If impossible — right or left 
transverse laparotomy, or a surgical approach to the sig-
moid colon with the sparing of the left straight muscle and 
white line of the abdomen; no perioperative hemotransfu-
sions for anemic patients, whose blood loss wasn’t asso-
ciated with hemorrhagic shock or coagulopathy; no rou-
tine drains, nasogastric tubes or catheters, extubation by 
the end of the operation.
3. Postoperative period: early enteral nutrition — 
mean 8–12 hours after surgery; early activisation 
on the day of surgery; prolonged epidural analgesia (up 
to 3 days) with local anesthetics, NSAIDs, diminishing 
of opioids; preventing postoperative nausea and vomi-
ting — 5-НТ3 blockers administration; restriction of 
perioperative infusions — 1700–2400 ml of rather col-
loids or crystalloids daily with total osmolarity no more 
than 75 mmol/l.
Control group patients received similar surgical 
treatment, but without the application of the above 
mentioned components of the ERP. Cancer staging was 
carried out according to American Joint Committee on 
Cancer (AJCC) Classification of Malignant Tumors 
TNM (7th ed., 2010). Antibiotical and antithrombotic 
prophylaxis had been provided in according to ESMO 
(European Society of Medical Oncology) and NCCN 
(National Comprehensive Cancer Network) guidelines. 
Postoperative complications were assessed according 
to Clavien — Dindo classification (2004). A postope-
rative complication was defined as any deviation from 
a normal postope rative period, revealed up to 30 days 
post surgery. Patients with stages IIB–C, III and IV un-
derwent adjuvant treatment as stated in NCCN (Na-
tional Comprehensive Cancer Network) guidelines. 
The differen ces between the groups were assessed by 
statistical methods for nonparametric values — χ2 and 
Fisher exact T-test. Survival analysis was assessed ac-
cording to Kaplan — Meier method.
RESULTS AND DISCUSSION
Surgical treatment was provided for 230 patients. 
The main group included 130 patients, control group — 
100. No significant differences in age, gender and body 
mass index were observed. There were no significant in-
tergroup differences in rates of comorbidity and com-
plications of main disease. Patients’ characteristics by 
primary tumor site is presented in Table 1. Main group 
patients had a trend towards right colon cancer, control 
group — the sigmoid colon (р < 0.05).
Table 1
Patients’ characteristics by primary tumor site
Tumor site Main group,  n (%)
Control group,  
n (%)
Caecum 33 (25.0) 22 (22.0)
Ascending colon 41 (31.0) 23 (23.0)
Right flexure 18 (14.0) 15 (15.0)
Transverse colon 10 (8.0) 4 (4.0)
Left flexure 8 (6.0) 3 (3.0)
Descending colon 11 (9.0) 7 (7.0)
Sigmoid colon 9 (7.0) 26 (26.0)
Total 130 (100) 100 (100)
Patients distribution by tumor stage is presented in 
Table 2. The main group had much more patients with 
moderate and poorly differentiated, and locally advanced 
tumors — 15.0 and 6.0% (р < 0.05), respectively. Ta-
king into account the distribution by primary tumor site, 
right hemicolectomy was the predominant type of sur-
gery in both groups. The structure of surgical procedures 
is shown in Table 3.
Postoperative complications. Among the patients 
from the main group, postoperative complications 
were observed in 11 (8.5%) cases. The structure of 
postope rative complications in both groups is shown 
in Table 4. There were no patients with more than one 
complication. Grade II complications (postoperative 
ileus) — 1 (0.8%); grade III — 4 (3.1%) — wound site 
infection, intraabdominal abscess and anastomotic 
leakage with an external fistula formation; grade IV — 
6 (4.6%): 2 cases — acute mesenteric ischemia, 2 — 
anastomotic leak, 1 — intraabdominal abscess, 1 — 
diffuse peritonitis. One case of postoperative morta-
lity was observed (0.8%).
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Table 2
Patients’ distribution by tumor stage
AJCC stage pTNM, 7th ed. Main group, n (%)
Control 
group, n (%)
І T1–2N0M0 1 (0.8) 7 (7.0)
ІІА T3N0M0 18 (14.0) 38 (38.0)
ІІВ T4aN0M0 52 (40.0) 12 (12.0)
IIC T4bN0M0 10 (8.0) 3 (3.0)
ІІІА T1–2N1M0 11 (8.2) 1 (1.0)
ІІІВ T3N1–2M0 9 (7.0) 16 (16.0)
ІІІС T4N1–2M0 8 (6.0) 6 (6.0)
Locally  
advanced
T4bN0M0;  
T4bN1–2M0 19 (15.0) 6 (6.0)
IV T1–4N0–2M1 21 (16.0) 17 (17.0)
Grade of differentiation
G1 5 (4.0) 41 (41.0)
G2 75 (58.0) 46 (46.0)
G3 41 (32.0) 11 (11.0)
G4 9 (6.0) 2 (2.0)
Table 3
Structure of surgical procedures
Type of surgery Main group, n (%)
Control group, 
n (%)
Right hemicolectomy 95 (74.0) 62 (62.0)
Resection of transverse colon 5 (4.0) 0
Left hemicolectomy 22 (17.0) 12 (12.0)
Resection of sigmoid colon 7 (5.0) 26 (26.0)
Laparoscopic procedures 5 (4.0) 0
Multivisceral resections 19 (15.0) 6 (6.0)
Curative surgery 109 (84.0) 82 (82.0)
Palliative surgery 21 (16.0) 18 (18.0)
Table 4
Structure of postoperative complications in both groups  
(Clavien — Dindo)
Complication grade
Patient groups, n (%) Signifi-
canceMain group
Control 
group
I − − −
II 1 (0.8) 4 (4.0) р < 0.05
III 4 (3.1) 4 (4.0) р = 0.574
IV 6 (4.6) 12 (12.0) р < 0.05
V (postoperative mortality) 1 (0.8) 2 (2.0) р < 0.05
Overall complications 11 (8.5) 20 (20.0) р < 0.05
Patients with complications 11 (8.5) 18 (18.0) р < 0.05
Patients with > 1 complication 0 2 (2.0) р < 0.05
In the control group the postoperative complications 
were observed in 20 (20.0%) cases. 2 (2.0%) patients 
had two postoperative complications. Grade II com-
plications included postoperative pneumonia (2.0%), 
peroneal vein thrombosis (1.0%), transitory cerebral 
ischemia (1.0%). Grade III complications included 
anastomotic leak with the external fistula formation 
(4.0%). Grade IV complications included anastomo tic 
leak with peritonitis (8.0%), postoperative adhesion-
al ileus (4.0%). Postoperative mortality was detected 
in 2 (2.0%) cases. Significant increase in rates of both 
postoperative morbidity and mortality was observed in 
control group (р < 0.05).
Long-term outcomes. The average observation peri-
od for patients in both groups was 37.4 ± 4.7 months. 
4 (3.1%) patients from the main group and 5 (5.0%) from 
control were lost for contact. Long-term parameters for 
the main and control groups are shown in Table 5.
Overall 3-year survival among patients with stage I–
III colon cancer after the curative surgery had a signi-
ficant difference in both groups — 88.4 ± 9.6% for 
the main group and 72.2 ± 7.6% for the control one 
(р < 0.05). There were no statistically significant dif-
ferences in overall 3-year recurrence-free survival — 
87.0 ± 7.5% and 90.0 ± 10.2%, respectively (р = 0.235). 
Survi val plots are presented in Figure.
Figure. Survival plots for overall 3-year survival for patients of 
main and control group
In both groups the patients who had postopera-
tive grade II–IV complications after the curative sur-
gery experienced a significant decrease of overall surviv-
al. Three-year survival wasn’t achieved in either of the 
groups. Median survival was 28.7 and 26.2 months, re-
spectively. The difference between groups was insigni-
ficant (р = 0.954).
Enhanced recovery concept is not new. Since early 
90s it intrenched itself in many clinics and gained wide 
acceptance in cardiac surgery, orthopedics and trauma-
tology, urology, gynecology, and others [3]. More and 
more data demonstrate multiple benefits of this strategy 
not only for patients, but for healthcare administrators as 
well. The most important among these convincing fac-
tors traditionally are the reduction of postoperative re-
covery, the terms of hospital stay, the postoperative com-
plications rates decrease, the quality of life improvement 
and the cost-effectiveness of treatment, that’s why it is 
widely accepted in multiple protocols of standard surgi-
cal care [1, 3, 10]. But in parallel with the growing prog-
ress in understanding of the fundamental mechanisms 
Table 5
Long-term parameters for main and control group
Study parameter
Number of patients, 
n (%)
Overall 3-year  
survival, n (%)
Overall disease-free 
3-year survival, n (%)
Median survival 
(months) рMain 
group
Control 
group
Main 
group
Control 
group
Main 
group
Control 
group
Main 
group
Control 
group
Patients underwent curative surgery 105 (81.0) 77 (77.0) 88.4 ± 9.6 72.2 ± 7.6 87.0 ± 7.5 90.0 ± 10.2 − − р = 0.578
Patients who had grade III–IV complications 11 (8.5) 20 (20.0) − − − − 28.7 26.2 р = 1.954
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of an organism stress response to traumatic, metabolic, 
neuroendocrine and immunologic shifts in colorectal 
cancer patients, some questions arise inevitably: is such 
pathologically based program, aimed at strictly deter-
mined pathologic events blockage, capable of granting 
with something more than reduction of the of hospital 
stay length and postoperative morbidity? 
G. Snyder et al. in their review suggest, that a condi-
tion of perioperative immunosuppression persistently ex-
ists in all colorectal cancer patients who undergo a sur-
gery. The main trigger factors of this condition are both 
surgical injury, accompanied by the increase of proin-
flammatory mediators expression and cytokines, and an-
esthesiological components (inadequate anesthesia, in-
fusion overload, opiates use) [11]. J. Coffey et al. point 
out stable lesions of cellular immunity in patients, who 
underwent colonic resections for cancer: reduced con-
centration of proinflammatory cytokines — IL-2, IL-6, 
IFN-γ and increased level of anti-inflammatory ones 
(IL-10), reduced level of circulating dendritic cells, NK-
lymphocytes, T-killers and cytotoxic T-lymphocytes, 
which gains peak on postope rative day 3 [12]. The impact 
of acquired immunosuppression on the colorectal cancer 
progression was pro ven in both clinical and experimen-
tal studies on animal models [13, 14]. Despite the exis-
tence of a link between severe postoperative complica-
tions (in particular, anastomotic leak) and worse survival 
in patients with colorectal, gastric and esophageal cancer 
isn’t something new for more than 10 years, pathologic 
pathways, explaining this trend, still remain unclear [8]. 
In a study of Х. Xia et al. it is stated that systemic inflam-
matory response syndrome development is a key element 
in this sequence of adverse events deve lopment, affec-
ting long-term results of colorectal cancer surgical treat-
ment [6]. According to the results of multivariate analysis, 
conducted by those authors, two independent prognos-
tic factors for the poor survival after the surgical treat-
ment of colorectal cancer are the regional lymph nodes 
involvement and the presence of grade II complications 
and higher. Overall 5-year survival for patients with stage 
I–III disease was 78.5% for patients without grade II–
IV complications and 41.4% if they were present. Over-
all 5-year disease-free survival was 82.1 and 40.9%, re-
spectively. Similar correlation was also observed in our 
study. Patients who developed grade II–IV complica-
tions after the curative surgery showed poor long-term 
outcomes — 3-year survival was not achieved in either of 
the groups with median survival of 28.7 and 26.2 months, 
respectively. On the other hand, patients who didn’t have 
complications demonstrated similarly satisfying results 
for both overall and disease-free survival — 90.0 ± 9.7 
and 92.0 ± 9.2%.
Hypothesis of the key role of systemic inflammatory 
response syndrome in tumor progression development 
was confirmed by the study of A. Mantovani et al. [15]. 
Since the main inflammatory mediators and their recep-
tors are responsible for the cell motility, invasive pattern 
and apoptosis blockage, increase of their concentration, 
induced by the systemic inflammatory response, is capa-
ble of increasing the metastatic potential of the free cir-
culating cancer cells. The same statement found confir-
mation for patients undergoing surgery for breast cancer 
as well [16]. Another point of view is shared by K. Wal-
ker et al., according to which the dissemination of tumor 
cells takes place in cases of anastomotic leak, affecting 
patient’s survival [17]. However, the studies of H. Ptok 
et al. disproved this statement by comparing the frequen-
cy of local recurrence rate in patients who had anasto-
motic leak and in in vivo models [18]. Despite the fact 
that the molecular pathologic pathways of tumor pro-
gression development in patients with grade II and high-
er complications still remain unclear, the key role of sys-
temic inflammatory response syndrome, state of chronic 
inflammation, causing immunosuppression and affect-
ing long-term outcomes doesn’t raise any doubts. In the 
study of T. Paholyuk et al., it is demonstrated, that the 
main factors of systemic inflammation, such as leuko-
cytes level, C-reactive protein and core body tempera-
ture remained more elevated particularly in the subgroup 
of patients, who had poor long-term outcomes after the 
surgical treatment of colorectal cancer [19]. It is notable 
that similar correlations between the laboratory param-
eters of the systemic inflammation and survival were ob-
tained by T. Kubota et al. for surgical treatment of gas-
tric cancer [20].
CONCLUSIONS
1. Developed ERP of surgical treatment of patients 
with colon cancer gives an opportunity to not only im-
prove the short-term outcomes, but to influence long-
term outcomes by means of postoperative grade II–IV 
complications reduction.
2. Multimodal ERP implementation resulted in re-
duction of postoperative morbidity by 11.6% and mor-
tality — by 1.2% among patients, who underwent cura-
tive surgery for colon cancer.
3. Postoperative grade II–IV complications were as-
sociated with the dramatic decrease in survival — 3-year 
survival was not achieved, median survival resulted in 
28.2 and 26.7 months in main and control group, re-
spectively.
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ВЛИЯНИЕ пОсЛЕОпЕРАЦИОННыХ 
ОсЛОЖНЕНИЙ И пРИМЕНЕНИЯ 
МуЛЬтИМОДАЛЬНОЙ пРОГРАММы 
БыстРОГО ВОсстАНОВЛЕНИЯ 
НА ОтДАЛЕННыЕ РЕЗуЛЬтАты 
ХИРуРГИЧЕсКОГО ЛЕЧЕНИЯ БОЛЬНыХ 
РАКОМ ОБОДОЧНОЙ КИШКИ
Е.А. Колесник, И.И. Лесной, А.А. Шудрак, 
А.В. Лукашенко, Д.Э. Махмудов, А.А. Бурлака
резюме. Применение мультимодальной программы 
быстрого восстановления (ПБВ) продемонстри-
ровало свою эффективность в отношении непо-
средственных результатов хирургического лече-
ния больных раком ободочной кишки. На сегодня 
влияние ПБВ на отдаленные результаты терапии 
остается недостаточно изученным. Цель: оценить 
влияние ПБВ на отдаленные результаты хирурги-
ческого лечения больных раком ободочной кишки. 
Объект и методы: включены 230 пациентов, ко-
торым в период с 2008 по 2013 г. проводили хирур-
гическое лечение по поводу рака ободочной кишки. 
В основную группу (хирургическое лечение по ПБВ) 
включено 130, в группу сравнения (стандартная 
тактика) — 100 больных. Результаты: значимых 
межгрупповых различий по антропометрическим 
данным, локализации опухоли, стадии заболева-
ния и объему оперативного вмешательства не от-
мечено. Среди пациентов основной группы после-
операционные осложнения II–IV класса по класси-
фикации Clavien — Dindo зарегистрированы в 11 
(8,5%), а контрольной группы — в 20 (20,0%) слу-
чаях (р < 0,05). Послеоперационная летальность 
составила 0,8 и 2,0% соответственно (р < 0,05). 
Период наблюдения — 37,4 ± 4,7 мес. Общая 3-лет-
няя выживаемость имела достоверное различие: 
88,4 ± 9,6% — в основной и 72,2 ± 7,6% — в конт-
рольной группе (р < 0,05). Общая 3-летняя без-
рецидивная выживаемость составила 87,0 ± 7,5 
и 90,0 ± 10,2% для основной и контрольной груп-
пы соответственно (р = 2,235). У пациентов обе-
их групп, у которых возникли послеоперационные 
осложнения II–IV класса, 3-летняя выживае-
мость не достигнута. Медиана — 28,7 и 26,2 мес 
для основной и контрольной группы соответствен-
но (р = 1,954). Выводы: применяемая ПБВ влияет 
на отдаленные результаты лечения за счет умень-
шения количества послеоперационных осложнений 
II–IV класса.
Ключевые слова: рак ободочной кишки, 
программа быстрого восстановления, 
отдаленные результаты хирургического 
лечения.
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